Organigram Global (NASDAQ:OGI), Canada’s leading recreational cannabis producer, reported record fourth-quarter and full-year results for the period ended September 30, 2025.
The company delivered its strongest financial performance to date, driven by substantial growth in both domestic and international markets, improved margins and continued operational expansion.
In the fourth quarter, Organigram generated gross revenue of $123.3 million, an increase of 76 percent from the prior year, while net revenue rose 79 percent to $80.1 million.
Adjusted gross margin reached $30.6 million, representing 38 percent, and adjusted EBITDA improved to $9.8 million, a 69 percent increase over last year, reflecting the company’s stronger product mix and efficiencies gained across production and distribution.
For the full fiscal year, Organigram reported gross revenue of $403.0 million, up 63 percent year-over-year, and net revenue of $259.2 million, representing a 62 percent increase.
Adjusted gross margin for the year was $91 million, or 35 percent, while adjusted EBITDA rose sharply to $21.9 million, a 160 percent jump from Fiscal 2024.
The company attributed the significant improvement primarily to scale, cost discipline and a growing contribution from higher-margin categories.